Introduction
Cryopreservation of supernumerary embryos produced during human IVF provides an opportunity for patients to have repeated attempts at conception following a single drug stimulation cycle, preventing wastage of valuable genetic material and improving cumulative pregnancy rates. This approach may have several advantages for the patient (Veeck, 2003; Anderson, 2005) . Firstly, it provides an opportunity to limit the numbers of embryos transferred while maximizing the usable embryo per oocyte retrieval cycle ratio at each stimulation attempt, a procedure that is costly and potentially difficult for patients. Secondly, the number of drug stimulation cycles in order to obtain oocytes can be decreased; consequently, the potential risk to the patient from exposure to anaesthesia and the possible development of hyperstimulation syndrome can be reduced. In addition, storage of embryos from a cycle allows the patient to space the timing of sibling pregnancies, and improve their potential to achieve a pregnancy at an advanced maternal age, since the eggs were retrieved when the patient was younger.
Successful cryopreservation of human embryos was first reported in 1983 by Trounson and Mohr with multicellular embryos that had been slow-cooled using dimethyl sulphoxide (DMSO). Subsequent modifications of the technique, introducing 1,2 propanediol and sucrose as cryoprotectants (Lassale et al., 1985) 608
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Comparison of open and closed methods for vitrification of human embryos and the elimination of potential contamination and slow cooling to -30°C prior to plunging into liquid nitrogen, resulted in the introduction of cryopreservation as a standard method offered by virtually every full-service IVF programme world-wide (Anderson et al., 2003) .
The primary disadvantages to slow cooling for human embryo cryopreservation are the requirement for an expensive programmable freezing machine and the time-consuming procedure. The introduction of a technique that could be performed without the use of costly equipment and could be completed by one cryopreservation specialist within minutes would provide significant benefits for any busy IVF programme.
Vitrification of embryos and oocytes may offer a solution for this problem. Vitrification can be defined as an extreme elevation in viscosity, i.e. solidification of solutions without ice crystal formation at low temperature (Liebermann et al., 2002a; Fuller and Paynter, 2004; Kasai, 2004; Liebermann and Tucker, 2004) . This phenomenon can be induced by either applying an extreme cooling rate or by using high concentrations of cryoprotectant solutions. Methods developed for vitrification in embryology use a combination of these two possibilities (Liebermann et al., 2003) . The advantages of vitrification in embryology may be considerable. Oocytes and embryos are sensitive to ice crystal formation; consequently, the elimination of this type of injury may increase their chances for survival. The required high cooling rate can be achieved by simple methods including, for example, direct plunging into liquid nitrogen, thus the need for expensive equipment is eliminated. Additionally, the time required for equilibration and cooling is considerably reduced. On the other hand, disadvantages of vitrification are the required high cryoprotectant concentration, and consequently the increased risk of toxic and osmotic damage, and the need to use special tools permitting high cooling rate by reducing radically the volume of solutions containing the embryos.
Successful vitrification of mammalian embryos was first reported by Rall and Fahy in 1985 . Since then, a number of cryoprotectant solutions have been investigated for human use including the use of DMSO, glycerol, ethylene glycol, propanediol and sugars in various combinations (Chen et al., 2000; Mandelbaum, 2000; Shaw et al., 2000; Wright et al., 2004) . In addition, numerous carrier systems have been tried, including electron microscope grids, open pulled straws, denuding pipettes, open hemi-straws, and cryoloops (Martino et al., 1996; Arav and Zeron, 1997; Vajta et al., 1998a,b; Lane et al., 1999; Kuleshova and Shaw, 2000; Park et al., 2000; Vanderzwalmen et al., 2000; Vandervorst et al., 2001; Yeoman et al., 2001; Liebermann and Tucker, 2002; Liebermann et al., 2002a,b; Mukaida et al., 2002 Mukaida et al., , 2003 Selman and ElDanasouri, 2002; Vanderzwalment et al., 2002 Vanderzwalment et al., , 2003 Isachenko et al., 2003; Son et al., 2003 Son et al., , 2005 Cremades et al., 2004; Walker et al., 2004) . While all of these systems have their advantages and disadvantages, the primary concern for many authorities and scientists is the potential risk of contamination for patients. As the rapid cooling in all these systems requires direct contact of the embryo containing solution and liquid nitrogen, there is a potential risk of disease transmission through contaminated liquid nitrogen during cooling and storage (Bielanski et al., 2000) .
The purposes of this study were: (i) to compare the efficacy of vitrification versus traditional slow cooling for cryopreservation of human embryos, and (ii) to investigate the possibility of replacing an earlier open system (Cryotop) with a newly introduced closed method (Cryotip TM ) to eliminate the potential danger of contamination.
Materials and methods

Patient treatment and embryo culture
Experiments were conducted in patients following informed consent and IRB approval. Patients were stimulated during an IVF cycle by the use of clomiphene citrate (Clomid; Shionogi Co. Ltd, Osaka, Japan). Clomiphene administration (50 mg/ day) was initiated on day 3 of the cycle and continued until the rise in LH, caused by the nasal administration of 300 μg of gonadotrophin-releasing hormone agonist (GnRHa) (Suprecur; Mochida Pharmaceutical Co. Ltd, Tokyo, Japan). Human menopausal gonadotrophin (HMG) (Humegon; Organon Co. Ltd, Netherlands) was initiated on day 8 (150 IU) and continued every other day until the administration of GnRHa.
Oocytes were recovered by using a transvaginal ultrasoundguided device (GM07M05V110; Mochida Pharmaceutical). After retrieval, oocytes were cultured in TCM199 medium buffered with 11 mmol/l Hepes, 9 mmol/l Na-Hepes and 5 mmol/l NaHCO 3 (referred further as TCM 199) supplemented with 10% Synthetic Serum Substitute (SSS; Irvine Scientific, Santa Ana, CA, USA) in 5% CO 2 in air at 37°C. After 2 h, insemination was performed by intracytoplasmic sperm injection (ICSI). The following day, fertilized oocytes with 2 pronuclei and two polar bodies were transferred into 0.5 ml droplets of Quinn's Advantage Cleavage Medium (Sage BioPharma, USA) supplemented with 10% SSS and cultured further as described above. Embryos that developed beyond the 4-cell stage on day 5 were transferred into 100 μl droplets of blastocyst medium (Irvine Scientific) and cultured under identical conditions to day 6 after ICSI.
Vitrification of embryos
Equilibration, vitrification, thawing, dilution and washing solutions were equivalents to those in Vit Kit (Irvine Scientific). At the time of vitrification embryos were transferred into equilibration solution (ES) consisting of 7.5% (v/v) ethylene glycol and 7.5% (v/v) DMSO dissolved in TCM199 supplemented with 20% SSS at 27°C for 5-15 min. After an initial shrinkage, embryos regained their original volume, and were transferred into three 20 µl drops of vitrification solution (VS) consisting of 15% (v/v) EG and 15%(v/v) DMSO and 0.5 mol/l sucrose dissolved in TCM199 supplemented with 20% SSS, After incubation for 20 s in each drop respectively, embryos were loaded into CryoTips™ (Irvine Scientific) or on Cryotops and plunged into liquid nitrogen.
CryoTip consists of a plastic straw with a thin part (250 μm inner diameter, 20 μm wall thickness and 3 cm length) connected to a thick part (2000 μm inner diameter and 150 μm wall thickness, 4.5 cm length) and equipped with a movable protective metal sleeve (Figure 1 ). Embryos were loaded in approximately 1 μl solution into the narrow part of the CryoTips without any air bubbles by aspiration of medium, embryo and medium, and medium by a connected syringe. Subsequently, the straw was heat-sealed at both ends, the protective sleeve was pulled over the narrow part and the device was plunged into liquid nitrogen. The time required for loading, sealing, adjustment of the sleeve For warming, CryoTip was removed from liquid nitrogen, plunged into a 37°C water bath for 3 s, wiped with 70% ethanol and a paper towel and the sealed ends were cut with a sterile scissor. By using a syringe adjusted to the thick end of the straw, the contents were expelled onto a sterile Petri dish. Solutions used for further manipulations were kept at 27°C. A 1 μl aliquot of thawing solution (TS) consisting of 1.0 mol/l sucrose in TCM199 plus 20% SSS was placed adjacent to the expelled drop and merged subsequently with the other drop containing the embryos. After 1 min, embryos were retrieved and transferred to a second drop of TS for 1 min, then transferred to two 20 μl drops of dilution solution (DS) consisting of 0.5 mol/l sucrose in TCM199 plus 20% SSS for 2 min each. After three subsequent washings through three successive 20 μl drops of washing solution (WS; TCM199 supplemented with 20% SSS) for 3 min each, embryos were transferred into 100 μl droplets of Blastocyst medium (Irvine Scientific) and cultured under conditions described earlier.
Cryotop (Kitazato Supply Co., Fujinomiya, Japan), consists of a 0.4 mm wide × 20 mm long × 0.1 mm thick polypropylene strips attached to a plastic handle and equipped with a cover straw (Figure 2 ; Kuwayama et al., 2005) . When using the Cryotops, after equilibration as described above, individual embryos a c b d were picked up in an extremely small volume (<0.1 µl) of VS, placed on the strip, and submerged into filtered liquid nitrogen. Subsequently, under the liquid nitrogen , the plastic cover was placed over the strip to provide protecting during storage.
For warming of the Cryotop, the protective cover was removed in liquid nitrogen and the end of the polypropylene strip was immersed directly into 4.5 ml of 37°C TS for 1 min. Embryos were then transferred into 4.5 ml of 37°C DS for 3 min, then washed twice in WS for 5 min each, and cultured as described previously.
Measurement of cooling and warming rates at vitrification
An ultra-fine thermocouple probe (0.1 mm diameter; Chino Ltd, Tokyo, Japan) was introduced into the small droplet on Cryotop or the liquid column of CryoTip. Subsequently, the tools were submerged directly into liquid nitrogen, held briefly inside, and then warmed in a 37°C water bath. Temperature changes were measured with an electronic thermometer (Model EB22005, Chino Ltd). For each method, the time required for the temperature to drop from -20 to -100°C (or the reverse) was measured during cooling and during warming of five replicates each, and the average cooling and warming rates were calculated.
Slow cooling
For comparison with standard methods of cryopreservation, human embryos were frozen in 1.5 mol/l propylene glycol plus 0.1 mol/l sucrose dissolved in Hepes-buffered P1 medium. Embryos were exposed to the cryoprotectant solutions, then aspirated into 0.25 ml straws and cooled to -6°C. After seeding, further cooling was performed in a programmable freezer (Planer Co. Ltd, UK) at 0.3°C/min to -35°C before plunging straws into liquid nitrogen. Frozen straws were thawed rapidly, and propylene glycol was removed by stepwise dilution (Lassale et al., 1985) .
Evaluation methods
The efficacy of cryopreservation was assessed in vitro by survival (i.e. normal response to osmotic changes during the dilution process) and developmental rates (for embryos cryopreserved at 2PN and 4-cell stage, respectively) and in vivo after embryo transfer by pregnancy rates and delivery rates. Invitro development of 2PN stage embryos was assessed on day 6 after ICSI. Embryos that developed to the blastocyst stage were transferred. Surviving cryopreserved and thawed blastocysts were cultured in vitro for 3-4 h before transfer.
Embryo transfer and pregnancy detection
All embryo transfers were performed non-surgically with ultrasound guide. Pregnancy was diagnosed by the formation of the gestational sacs by ultrasound observations at 6 weeks after the last menstrual period.
Statistics
Data were analysed by the chi-squared test. P-values ≤0.05 were regarded as significant.
Results
In the first series of experiments, the efficiency of vitrification with slow rate freezing was compared by using human embryos at various stages of development. The vitrification procedure used in these trials was the Cryotop method.
The survival and developmental rates for pronuclear-stage human embryos cryopreserved by either slow cooling or vitrification are shown in Table 1 . Vitrification resulted in higher survival, developmental rates than slow cooling. Vitrification was also more efficient than slow cooling for cryopreservation of 4-cell state embryos and blastocysts (Tables 2 and 3 respectively). There was no difference in pregnancy and live birth rates between the two cryopreservation methods. On the other hand, pregnancy rates following blastocyst vitrification were higher than pregnancy rates of 4-cell embryos both after slow cooling and vitrification.
In the second series of experiments, the efficiency of the open and closed vitrification system, i.e. the Cryotop and CryoTip method, was compared. As shown in Table 4 , there were no significant differences between the two with regard to survival, pregnancy rates, implantation rates, or delivery rates.
The average values of the cooling and warming rates were 12,000 and 24,000°C/min with the CryoTip, and 23,000 and 42,000°C/min with the Cryotop method.
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Article -Vitrification of human embryos -M Kuwayama et al.
Discussion
Cryopreservation of embryos is a critical step in maximizing the efficiency of an IVF cycle for patients. Clinical success with cryopreservation seems to be highly variable from laboratory to laboratory, and may depend on many factors including patient age and stimulation protocol, quality of embryos selected for freezing, developmental stage at freezing, media formulation including type of cryoprotectants used, parameters of cooling and warming, and type and quality control of programmable freezing unit employed. The latter problem, however, occurs only at slow cooling, as vitrification does not require sophisticated equipment of questionable reliability at certain makes and types. Variations caused by different media and cryoprotectants can also be minimized by using commercially available kits, recently also produced for vitrification (by, for example, Irvine Scientific, Kitazato). On the other hand, according to previous publications, and also confirmed by the present work, results achieved by vitrification are at least equal or significantly better than those obtained with traditional slow cooling for cryopreservation of mammalian oocytes and embryos including humans (Kuleshowa and Lopata, 2002; Liebermann et al., 2003; Smith and Silva, 2004; Walker et al., 2004; Kuwayama et al., 2005) .
Moreover, a considerable number of publications reported normal in-vitro and in-vivo development following human oocyte, early embryo and blastocyst vitrification (Yokota et al., 2000; Jelinkova et al., 2002; Selman et al., 2002; Isachenko et al., 2003 Isachenko et al., , 2004a Katayama et al., 2003; Liebermann et al., 2003b; Son et al., 2003; Huang et al., 2004; Rienzi et al., 2004; Smith et al., 2004; Son et al., 2005) , as well as deliveries Values within rows with different superscripts are significantly different (P < 0.01). Table 3 . Survival and pregnancy rates with human blastocysts cryopreserved by either slow cooling as compared with vitrification using the Cryotop method. Values within rows with different superscripts are significantly different (P < 0.05).
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of healthy births (El-Danasouri and Selman, 2001; Yokota et al., 2001a,b; Vanderzwalmen et al., 2002; Mukaida et al., 2003; Kuwayama et al., 2005 (Bielanski et al., 2000) . Accordingly, a number of governing bodies worldwide have expressed concern about the potential risk. Previous attempts to eliminate this danger included cooling performed in liquid nitrogen filtered through a 0.2 μm pore-size filter and placing the carrier tool into a container that partially or completely isolates it from the liquid nitrogen during storage (Vajta et al., 1998; Kuwayama et al., 2005) .
As proven by the present work, the newly developed CryoTip method may provide a simple and practical solution to the problem. After loading, the plastic straw can be heat-sealed on both ends, and consequently the solution containing the embryo and the liquid nitrogen is hermetical isolated during cooling and storage. On the other hand, although the isolation slightly decreased the rate of cooling, the values that could be obtained with the CryoTip were still high enough to obtain appropriate vitrification. Consequently, embryo survival, as well as in-vitro and in-vivo developmental data, was identical to those achieved by the open Cryotop vitrification system. An additional benefit of the CryoTip vitrification is that any embryologist familiar with the usual method of loading and sealing 0.25 ml cryostraws will easily accommodate to using the smaller volume, but similar approach in handling, of the CryoTip. Moreover, the protective metal sleeve ensures safe storage of the CryoTip in a relatively small space, and the sleeve as well as the wide part of the plastic tube offers enough space for proper marking of straws for safe identification.
Recently, Isachenko et al. (2005) published a method for aseptic vitrification of human zygotes by using open pulled straws (Vajta et al., 1998) hermetically isolated from liquid nitrogen before cooling. According to the authors, the considerably decreased cooling rate achievable by this technique did not compromise survival and further development. This observation is in contrast to unpublished observations, and seems to contradict the principles of many previous ultrarapid vitrification methods (Martino et al., 1996; Vajta et al., 1998; Lane et al., 1999; Park et al., 2000; Vanderzwalmen et al., 2000; Liebermann and Tucker, 2002; Katayama et al., 2003; Mukaida et al., 2003; Kuwayama et al., 2005) . Moreover, it may also be questioned if the physical phenomenon of vitrification could be obtained by using the applied cryoprotectant concentrations and the achievable cooling rate in the method of Isachenko et al. (2005) . Based on these concerns, further comparative investigations performed by independent groups might be required to determine the difference in efficiency and practical value of the two approaches.
In conclusion, the present results, based on more than 16,000 human embryo cryopreservations, prove that vitrification is a simple, inexpensive and safe alternative of traditional slow cooing resulting in higher survival and in-vitro developmental rates for PN, multicellular and blastocyst stage human embryos. Pregnancy and live birth dates did not differ between the two methods. Additionally, the newly developed CryoTip TM technology eliminates the danger of contamination while maintaining the high efficiency of the procedure.
